title: Body dysmorphic disorder.
abstract: Body dysmorphic disorder (BDD) can be a severe and often debilitating psychiatric disorder that has been largely under-recognized and underdiagnosed. Pharmacologic and nonpharmacologic treatment options are available but limited. This review aims to provide an updated overview of the psychopathology and epidemiology of BDD, with an emphasis on current pharmacologic and nonpharmacologic treatment options for BDD.
authors.affiliation: OCD and Related Disorders Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, 2nd Floor, Boston, MA 02114, USA.
authors.forename: Angela
authors.initials: A
authors.lastname: Fang
authors.affiliation: OCD and Related Disorders Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, 2nd Floor, Boston, MA 02114, USA.
authors.forename: Natalie L
authors.initials: NL
authors.lastname: Matheny
authors.affiliation: OCD and Related Disorders Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, 2nd Floor, Boston, MA 02114, USA. Electronic address: wilhelm@psych.mgh.harvard.edu.
authors.forename: Sabine
authors.initials: S
authors.lastname: Wilhelm
mesh_terms: D057215:Body Dysmorphic Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D015897:Comorbidity; D003702:Delusions / Q000453:epidemiology; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000453:epidemiology; D010342:Patient Acceptance of Health Care / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013405:Suicide
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors
keywords: Body dysmorphic disorder; Cognitive-behavioral therapy; Obsessive-compulsive spectrum; Serotonin reuptake inhibitor; Treatment